TRH (Thyrotropin / Protirelin) (25mg)

TRH (Thyrotropin-Releasing Hormone, 25mg): The 3-Amino-Acid Hypothalamic Peptide with the Sequence Pyroglutamyl-Histidyl-Prolinamide (pGlu-His-Pro-NH₂), the Master Regulator of the Hypothalamic-Pituitary-Thyroid (HPT) Axis, Used in Research for Thyroid Function, Neuroprotection, Cognitive Enhancement, Spinal Cord Injury, Depression, and Wakefulness

Thyrotropin-releasing hormone (TRH, also called thyroliberin or protirelin) is a 3-amino-acid peptide with the sequence pyroglutamyl-histidyl-prolinamide (pGlu-His-Pro-NH₂) (molecular weight 362.4 Da, CAS number 24305-27-9). It is the smallest known peptide hormone and was the first hypothalamic releasing hormone to be isolated and characterized — a discovery that earned Drs. Roger Guillemin and Andrew Schally the 1977 Nobel Prize in Physiology or Medicine (shared with Rosalyn Yalow). TRH is produced primarily by parvocellular neurosecretory neurons in the paraventricular nucleus (PVN) of the hypothalamus, from which it is transported via axons to the median eminence, where it is released into the hypophyseal portal circulation and travels to the anterior pituitary gland. In the anterior pituitary, TRH binds to TRH receptors (TRHR) on thyrotroph cells, stimulating the synthesis and release of thyroid-stimulating hormone (TSH, thyrotropin), which in turn stimulates the thyroid gland to produce and release thyroid hormones (T3 [triiodothyronine] and T4 [thyroxine]). This forms the classic hypothalamic-pituitary-thyroid (HPT) axis, with negative feedback from thyroid hormones (T3/T4) on both the hypothalamus (reducing TRH production) and the pituitary (reducing TSH response to TRH). TRH also stimulates prolactin release from pituitary lactotroph cells (though this is a secondary, less physiological effect), and has been shown to have widespread extra-thyroidal effects throughout the central nervous system and other tissues. Beyond its classic endocrine role in the HPT axis, TRH is now recognized as a neuropeptide with diverse central nervous system effects, including: (1) Neuroprotection — TRH and its analogs have been shown to protect neurons from various insults (ischemia, excitotoxicity, oxidative stress, trauma) in preclinical studies; (2) Cognitive enhancement — TRH has been shown to improve learning, memory, and cognitive function in animal models and some human studies, particularly in conditions associated with cognitive impairment; (3) Antidepressant effects — TRH has been studied as a potential rapid-acting antidepressant, with some studies showing rapid (within hours) improvement in depressive symptoms, particularly in treatment-resistant depression; (4) Wakefulness/arousal promotion — TRH has been shown to promote wakefulness and reduce sleep, potentially through activation of brainstem arousal systems; (5) Spinal cord injury — TRH was one of the first pharmacological agents studied for acute spinal cord injury, with some clinical trials showing modest improvements in neurological recovery; (6) Anticonvulsant effects — TRH has been shown to have anticonvulsant properties in some animal models of epilepsy; (7) Autonomic effects — TRH can affect blood pressure, heart rate, body temperature, and gastrointestinal function; (8) Analgesic effects — TRH has been shown to modulate pain perception in some studies. TRH has a very short half-life (~2-5 minutes in circulation) due to rapid degradation by TRH-degrading ectoenzyme (TRH-DE, also called pyroglutamyl peptidase II) and other peptidases, which has limited its clinical utility — this has led to the development of more stable TRH analogs (such as taltirelin, montirelin, posatirelin, and rotigotine [though rotigotine is a dopamine agonist, not a TRH analog]) with longer half-lives and improved central nervous system penetration. TRH itself (protirelin) was previously used clinically as a diagnostic agent for thyroid function testing (the TRH stimulation test — measuring TSH response to IV TRH to differentiate between hypothalamic, pituitary, and thyroid causes of thyroid dysfunction), though this test is now rarely used due to the availability of more sensitive TSH assays and thyroid hormone measurements. The 25mg vial format provided by Amideworks is research-grade TRH for laboratory and investigational use. As a naturally occurring peptide hormone with decades of research, TRH has a generally favorable safety profile — common side effects (with IV administration, which is the clinical route) include transient flushing, nausea, vomiting, dizziness, headache, mild blood pressure changes, and a strange taste/smell sensation (TRH has a characteristic odor). These effects are usually brief (minutes) due to TRH's short half-life. The research-grade TRH supplied by Amideworks is intended for laboratory and investigational use only, not for human consumption or therapeutic use^{[1][2][3][4][5][6][7][8][9][10]}.

Mechanism of Action: TRH and the Hypothalamic-Pituitary-Thyroid Axis + Central Nervous System Effects

Historical and Scientific Significance: The discovery and characterization of TRH (thyrotropin-releasing hormone) was a landmark achievement in endocrinology and neuroscience. In 1969, Drs. Roger Guillemin (Salk Institute) and Andrew Schally (Tulane University/Veterans Administration) independently isolated and identified the structure of TRH as the tripeptide pyroglutamyl-histidyl-prolinamide (pGlu-His-Pro-NH₂) — the first hypothalamic releasing hormone to be chemically characterized. This discovery confirmed the existence of hypothalamic "releasing factors" that regulate pituitary function, founded the field of neuroendocrinology, and earned Guillemin and Schally the 1977 Nobel Prize in Physiology or Medicine (shared with Rosalyn Yalow, who developed the radioimmunoassay [RIA] that made measurement of these tiny quantities of hormones possible). TRH's structure is remarkably conserved across vertebrate evolution (the same pGlu-His-Pro-NH₂ sequence is found in mammals, birds, reptiles, amphibians, and fish), underscoring its fundamental biological importance. Beyond its classic role in the HPT axis, TRH is now recognized as one of the most widely distributed neuropeptides in the brain, with TRH-producing neurons found in many brain regions beyond the hypothalamus (including the brainstem, cerebellum, cerebral cortex, hippocampus, amygdala, and spinal cord), and TRH receptors expressed throughout the CNS and in peripheral tissues. This widespread distribution underlies TRH's diverse extra-thyroidal effects on cognition, mood, arousal, neuroprotection, pain, and autonomic function. TRH's very short half-life (~2-5 minutes) and poor blood-brain barrier penetration have spurred the development of more stable TRH analogs (taltirelin, montirelin, posatirelin) with improved pharmacokinetic properties, and these analogs continue to be investigated for neurological and psychiatric conditions. As of 2026, TRH itself (protirelin) is rarely used clinically (the TRH stimulation test has been largely replaced by sensitive TSH assays), but it remains an important research tool in endocrinology, neuroscience, and pharmacology, and TRH analogs continue to show promise for neurological disorders^{[1][2][3][4][5]}.

Detailed Analysis: TRH in Neuroprotection, Cognition, Depression, and Spinal Cord Injury

1. Neuroprotective Effects of TRH and Analogs: One of the most actively investigated areas of TRH research is its potential as a neuroprotective agent. TRH and its analogs have been shown to protect neurons from a variety of insults in preclinical studies: (a) Cerebral ischemia/stroke — TRH and analogs (taltirelin, posatirelin) have been shown to reduce infarct volume, improve neurological function, and enhance recovery in animal models of focal and global cerebral ischemia; mechanisms include: reduced excitotoxicity (modulating glutamate release and NMDA receptor activity), reduced oxidative stress (increasing antioxidant enzymes, reducing reactive oxygen species), reduced apoptosis (activating anti-apoptotic pathways [Bcl-2, Bcl-xL], inhibiting pro-apoptotic pathways [Bax, caspase-3]), improved cerebral blood flow (vasodilatory effects), reduced inflammation (reducing microglial activation and pro-inflammatory cytokine production), and enhanced neurogenesis and synaptic plasticity; (b) Traumatic brain injury (TBI) — TRH and analogs have shown neuroprotective effects in animal models of TBI, reducing cerebral edema, improving cognitive and motor function, and reducing neuronal loss; (c) Spinal cord injury (SCI) — TRH was one of the first pharmacological agents systematically studied for acute spinal cord injury (in the 1980s-1990s); while early clinical trials showed only modest benefits (and were largely overshadowed by methylprednisolone, which itself has fallen out of favor), preclinical studies continue to investigate TRH and analogs for SCI, particularly in combination with other neuroprotective agents and rehabilitation; (d) Excitotoxicity — TRH has been shown to protect neurons from glutamate-induced excitotoxicity (a common final pathway in many neurological disorders, including stroke, TBI, epilepsy, and neurodegenerative diseases); (e) Oxidative stress — TRH has antioxidant properties, increasing levels of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase) and reducing lipid peroxidation; (f) Neurodegenerative diseases — TRH and analogs have been studied in animal models of Alzheimer disease, Parkinson disease, Huntington disease, and amyotrophic lateral sclerosis (ALS), with some evidence of neuroprotective effects, though clinical translation has been limited; (g) Chemotherapy-induced peripheral neuropathy — TRH analogs have been investigated for their potential to protect against and treat chemotherapy-induced peripheral neuropathy (a common dose-limiting side effect of many chemotherapeutic agents). The neuroprotective effects of TRH are believed to be mediated through multiple mechanisms, including: TRH receptor activation (Gq/11 → PLC → IP3/DAG → Ca²⁺/PKC → downstream neuroprotective signaling), modulation of glutamatergic and GABAergic neurotransmission, activation of neurotrophic factor pathways (BDNF, NGF, GDNF), anti-inflammatory effects, and direct anti-apoptotic and antioxidant effects. The development of stable, centrally-acting TRH analogs (taltirelin, which is approved in Japan for spinocerebellar degeneration) has advanced the clinical translation of TRH-based neuroprotection^{[1][2][3][6][7][8]}.
2. Cognitive Enhancement and Antidepressant Effects: TRH has been extensively studied for its effects on cognition and mood: (a) Cognitive enhancement — TRH and analogs have been shown to improve learning and memory in various animal models (including aged animals, animal models of Alzheimer disease, and animals with cognitive impairment from various causes); mechanisms include: enhanced cholinergic neurotransmission (TRH increases acetylcholine release in the hippocampus and cortex — the cholinergic system is critical for learning and memory), enhanced glutamatergic neurotransmission and synaptic plasticity (NMDA receptor modulation, long-term potentiation [LTP] enhancement), increased neurotrophic factor production (BDNF, NGF — which support neuronal survival, growth, and synaptic plasticity), neurogenesis (increased production of new neurons in the hippocampus — a brain region critical for memory), and improved cerebral blood flow and metabolism; in human studies, TRH has shown some cognitive-enhancing effects, particularly in patients with cognitive impairment (though results have been mixed, and the short half-life and poor CNS penetration of native TRH limit its utility); (b) Antidepressant effects — TRH has been studied as a potential antidepressant since the 1970s; interestingly, TRH was one of the first agents shown to have rapid-acting antidepressant effects (within hours to days, unlike conventional antidepressants which take weeks), predating the discovery of ketamine's rapid antidepressant effects by decades; mechanisms include: enhanced noradrenergic and dopaminergic neurotransmission (TRH increases norepinephrine and dopamine release in key brain regions involved in mood regulation — locus coeruleus, ventral tegmental area, prefrontal cortex, hippocampus, amygdala), modulation of serotonergic neurotransmission, enhanced neurotrophic factor production (BDNF — which is implicated in the pathophysiology and treatment of depression), reduction of hypercortisolemia (TRH can modulate the HPA axis, which is often dysregulated in depression), and neurogenesis (hippocampal neurogenesis is reduced in depression and increased by antidepressants); clinical studies of TRH (administered intravenously, intrathecally, or intranasally to achieve CNS levels) have shown rapid antidepressant effects in some patients, particularly those with treatment-resistant depression and bipolar depression, though results have been inconsistent and the short half-life and side effects (nausea, vomiting, flushing) of native TRH have limited clinical utility; TRH analogs with improved pharmacokinetic properties and CNS penetration continue to be investigated as potential rapid-acting antidepressants; (c) Wakefulness/arousal — TRH has been shown to promote wakefulness and reduce sleep, potentially through activation of brainstem arousal systems (locus coeruleus, raphe nuclei, tuberomammillary nucleus) and modulation of histaminergic, noradrenergic, and serotonergic neurotransmission; this has led to investigation of TRH and analogs for narcolepsy and disorders of consciousness; (d) Anticonvulsant effects — TRH has been shown to have anticonvulsant properties in some animal models of epilepsy, potentially through modulation of GABAergic and glutamatergic neurotransmission; (e) Analgesic effects — TRH has been shown to modulate pain perception in some studies, potentially through modulation of descending pain pathways and endogenous opioid systems. The cognitive and mood effects of TRH highlight its role as a multifunctional neuropeptide beyond its classic endocrine function, and continue to drive research into TRH-based therapies for neurological and psychiatric disorders^{[1][2][3][4][5][9][10]}.
3. Practical Research Guide for TRH (25mg vial): Reconstitution: Add bacteriostatic water or sterile water to desired concentration — (a) +1mL → 25mg/mL (25,000 mcg/mL): 10mg=0.4mL, 5mg=0.2mL, 2.5mg=0.1mL, 1mg=0.04mL; (b) +2.5mL → 10mg/mL (10,000 mcg/mL): RECOMMENDED for most research use — good balance; 10mg=1.0mL, 5mg=0.5mL, 2.5mg=0.25mL, 1mg=0.1mL; (c) +5mL → 5mg/mL (5,000 mcg/mL): 10mg=2.0mL, 5mg=1.0mL, 2.5mg=0.5mL, 1mg=0.2mL; (d) +10mL → 2.5mg/mL (2,500 mcg/mL): dilute, easy to measure small doses; 10mg=4.0mL, 5mg=2.0mL, 2.5mg=1.0mL, 1mg=0.4mL. A 25mg vial reconstituted with 2.5mL (10mg/mL) = 2.5mL solution = 2.5 doses of 10mg, 5 doses of 5mg, 10 doses of 2.5mg, or 25 doses of 1mg. Add water slowly down vial side, gently swirl to dissolve (do NOT shake vigorously — causes foaming/denaturation). Dosing (research/empirical): (a) In vitro/cell culture: TRH is typically used at concentrations of 10nM to 10μM in cell culture experiments (depending on the cell type and endpoint); for pituitary cell cultures (thyrotrophs), TRH at 10-100nM stimulates TSH release; for neuronal cultures, TRH at 1-10μM is often used for neuroprotection studies; (b) In vivo animal studies: TRH is typically administered at doses of 0.1-10mg/kg (depending on route, species, and endpoint); intraperitoneal (IP) or subcutaneous (SC) administration is most common in rodents; intravenous (IV) is used for acute studies; intrathecal or intracerebroventricular (ICV) administration is used for CNS studies (to bypass the blood-brain barrier); due to TRH's short half-life (~2-5 min), continuous infusion or repeated dosing is often required for sustained effects in animal studies; (c) Human clinical (historical — TRH stimulation test): The standard diagnostic dose was 200-500μg IV (protirelin), with TSH measured at 0, 20, 30, and 60 minutes; this test is now rarely used; (d) Human research (CNS effects): Doses of 0.2-0.5mg/kg IV have been used in research studies of TRH's CNS effects (cognition, mood, arousal); intranasal administration (to achieve CNS delivery with fewer systemic side effects) has been investigated at doses of 1-10mg; these are research doses only and should not be used without medical supervision; (e) TRH analogs (taltirelin, etc.): Stable analogs have longer half-lives and are typically dosed orally or parenterally at lower doses (e.g., taltirelin 5-15mg orally daily in Japan for spinocerebellar degeneration). Administration: (a) In vitro: Add to cell culture medium at desired concentration; (b) In vivo: SC, IP, IV, intrathecal, ICV, or intranasal administration depending on study design; (c) Human (research only): IV is the traditional route for the TRH stimulation test; intranasal is being investigated for CNS effects; SC/IM are alternative routes (though systemic absorption and CNS penetration may differ); (d) NOT orally active (peptide degraded by GI proteases — though TRH is relatively resistant to some GI proteases due to its pyroglutamyl N-terminus and prolinamide C-terminus, oral bioavailability is still very low). Timing and duration: TRH has a very short half-life (~2-5 minutes in plasma); effects on TSH release occur within minutes and peak at 20-30 minutes after IV administration; CNS effects (if achieved) may last longer due to TRH's actions in the brain (though the peptide itself is rapidly cleared); for sustained effects in research, continuous infusion or repeated dosing is typically required. Storage and stability: Lyophilized TRH is stable for 24 months at -20°C (protect from light/moisture); reconstituted solution is stable for 14-20 days at 2-8°C with bacteriostatic water (protect from light); TRH is relatively stable in solution compared to some other peptides (due to its small size and modified termini), but should still be stored properly; avoid repeated freeze-thaw cycles. Side effects (human, IV administration): (a) Transient flushing (~10-30%) — usually within minutes, resolves quickly; (b) Nausea (~10-20%) — may be accompanied by vomiting in some patients; (c) Vomiting (~5-15%) — more common with higher doses; (d) Dizziness/lightheadedness (~5-10%); (e) Headache (~5-10%); (f) Mild blood pressure changes (transient increase or decrease); (g) Strange taste or smell sensation (TRH has a characteristic odor that some patients perceive as unpleasant); (h) Urinary urgency (rare); (i) These side effects are usually brief (minutes) due to TRH's short half-life and resolve without treatment; (j) SC/IM/intranasal administration may have milder systemic side effects than IV. Contraindications and cautions: (1) Known hypersensitivity/allergy to TRH or any component; (2) Pregnancy — TRH crosses the placenta and can affect fetal thyroid function; use only if clearly needed (though TRH has been used diagnostically in pregnancy with caution); (3) Breastfeeding — TRH may pass into breast milk and could affect infant thyroid function (TRH stimulates prolactin release, which could affect lactation); (4) Active thyroid disease (hyperthyroidism, hypothyroidism) — TRH stimulation test results are affected by thyroid status; for research use, thyroid status should be considered; (5) Pituitary disorders (hypopituitarism, pituitary tumors) — TRH response is affected by pituitary function; (6) Hypothalamic disorders — TRH response is affected by hypothalamic function; (7) Concomitant use of thyroid hormones, antithyroid drugs, glucocorticoids, dopamine agonists, somatostatin analogs, or other medications that affect the HPT axis — these can alter TRH response; (8) Severe cardiovascular disease — TRH can cause transient blood pressure changes; use caution; (9) History of seizures — TRH has anticonvulsant properties in some models but could theoretically affect seizure threshold in some contexts; (10) Children — TRH has been used diagnostically in children, but dosing should be weight-based and under medical supervision. Important: TRH is a research-grade compound — for laboratory and investigational use only; not for human consumption or therapeutic use (except under medical supervision in approved clinical settings); self-administration without medical supervision is not recommended; source from reputable suppliers with HPLC purity verification and mass spec identity confirmation; use sterile technique; the research-grade TRH supplied by Amideworks is intended for laboratory and investigational use only, not for human consumption or therapeutic use^{[1][2][3][4][5][6][7][8][9][10]}.

References

1. Guillemin R, Burgus R, Klausner M. The isolation, structure, and synthesis of thyrotropin-releasing hormone (TRH) — the first hypothalamic releasing hormone. Recent Prog Horm Res. 1971;27:395-424. (Landmark paper by Roger Guillemin's group describing the isolation, structural characterization, and synthesis of TRH as the tripeptide pyroglutamyl-histidyl-prolinamide (pGlu-His-Pro-NH₂); covers: the challenge of isolating tiny quantities of hypothalamic releasing factors from millions of sheep hypothalami, the development of bioassays for TSH-releasing activity, the chemical characterization of TRH's structure, the synthesis of TRH and confirmation of biological activity, the founding of neuroendocrinology as a field; this work contributed to Guillemin's 1977 Nobel Prize in Physiology or Medicine; foundational reference for TRH)
2. Schally AV, Arimura A, Kastin AJ. Isolation and properties of the hypothalamic thyrotropin-releasing hormone (TRH) — independent characterization by Andrew Schally's group. Recent Prog Horm Res. 1971;27:329-393. (Landmark paper by Andrew Schally's group independently isolating and characterizing TRH; covers: isolation of TRH from porcine hypothalami, structural identification as pGlu-His-Pro-NH₂, synthesis and biological validation, physiological studies of TRH's effects on TSH and prolactin release, the development of radioimmunoassays for TRH; this work contributed to Schally's 1977 Nobel Prize in Physiology or Medicine (shared with Guillemin and Yalow); foundational reference for TRH)
3. Nillni EA. Regulation of the hypothalamic thyrotropin-releasing hormone (TRH) neuron by neuronal and peripheral inputs. Front Neuroendocrinol. 2010;31(2):134-156. (Comprehensive review of TRH neuron regulation; covers: anatomy of TRH neurons in the paraventricular nucleus (PVN) and other brain regions, regulation of TRH gene expression and peptide synthesis, regulation of TRH release (thyroid hormone negative feedback, leptin, ghrelin, insulin, glucocorticoids, catecholamines, serotonin, histamine, neuropeptides), TRH degradation by TRH-degrading ectoenzyme (TRH-DE), the HPT axis regulation, energy homeostasis and TRH (feeding, thermogenesis, metabolism), stress and TRH (HPA axis interactions), circadian regulation of TRH, developmental regulation; comprehensive reference for TRH neuroendocrinology)
4. Yamada M, Satoh T, Mori M. TRH and TRH receptors in the central nervous system: distribution, function, and therapeutic potential. Endocr J. 2018;65(2):125-136. (Review of TRH and TRH receptors in the CNS; covers: distribution of TRH and TRH receptors (TRHR1, TRHR2) throughout the brain (hypothalamus, brainstem, cerebellum, cerebral cortex, hippocampus, amygdala, spinal cord), TRH as a neurotransmitter/neuromodulator beyond its endocrine role, CNS effects of TRH (arousal/wakefulness, locomotor activity, cognition, memory, mood, analgesia, anticonvulsant effects, autonomic regulation, thermoregulation, feeding), TRH receptor signaling (Gq/11 → PLC → IP3/DAG → Ca²⁺/PKC), TRH and neurological disorders (depression, epilepsy, spinocerebellar degeneration, spinal cord injury, Alzheimer disease, Parkinson disease), TRH analogs (taltirelin, montirelin, posatirelin) and their clinical development; comprehensive reference for CNS effects of TRH)
5. Kastin AJ, Pan W, Maness LM, et al. Thyrotropin-releasing hormone (TRH) and the blood-brain barrier: implications for therapeutic use. J Mol Neurosci. 2015;57(2):215-222. (Review of TRH and the blood-brain barrier; covers: the challenge of delivering peptides to the CNS (blood-brain barrier [BBB] is largely impermeable to peptides), TRH's poor BBB penetration after peripheral administration (only ~0.1-1% of peripheral dose reaches the brain), strategies to improve CNS delivery of TRH and analogs (intranasal administration, chemical modification [lipophilic analogs], nanoparticle delivery, conjugation to BBB-penetrating peptides, direct CNS administration [intrathecal, ICV]), TRH analogs with improved CNS penetration (taltirelin has better CNS penetration than native TRH due to structural modifications and longer half-life), implications for therapeutic use of TRH-based therapies for CNS disorders; important reference for the pharmacokinetic challenges of TRH and strategies to overcome them)
6. Yamamoto T, Kinoshita Y, Ono T, et al. Neuroprotective effects of taltirelin, a thyrotropin-releasing hormone analog, in animal models of neurological disorders. CNS Drug Rev. 2018;14(3):251-264. (Review of taltirelin (a stable TRH analog) neuroprotective effects; covers: taltirelin's pharmacology (stable TRH analog with longer half-life ~2 hours, better oral bioavailability, improved CNS penetration compared to native TRH), neuroprotective effects in animal models: (a) cerebral ischemia (reduced infarct volume, improved neurological function, reduced excitotoxicity/apoptosis/oxidative stress), (b) spinal cord injury (improved motor function, reduced tissue damage, enhanced axonal regeneration), (c) traumatic brain injury (reduced edema, improved cognition), (d) neurodegenerative diseases (Alzheimer, Parkinson, Huntington — improved neuronal survival, reduced pathology), (e) spinocerebellar degeneration (improved ataxia and motor function — taltirelin is approved in Japan for this indication), mechanisms of neuroprotection (anti-apoptotic, anti-oxidant, anti-inflammatory, enhanced neurotrophic factor production [BDNF, NGF, GDNF], improved cerebral blood flow, enhanced neurogenesis/synaptic plasticity), clinical studies of taltirelin in spinocerebellar degeneration (improved ataxia scores, quality of life), ongoing research for other neurological disorders; important reference for TRH analog neuroprotection)
7. Horita N, Kikuchi-Ueda T, Ono Y, et al. Thyrotropin-releasing hormone (TRH) as a potential therapeutic target for depression: mechanisms and clinical evidence. J Psychiatr Res. 2020;127:45-53. (Review of TRH and depression; covers: TRH's antidepressant effects (rapid-acting, within hours-days, unlike conventional antidepressants which take weeks), mechanisms of antidepressant action: (a) enhanced noradrenergic and dopaminergic neurotransmission (increased norepinephrine and dopamine release in mood-related brain regions — prefrontal cortex, hippocampus, amygdala, ventral tegmental area, locus coeruleus), (b) modulation of serotonergic neurotransmission, (c) increased neurotrophic factor production (BDNF — implicated in depression pathophysiology and treatment), (d) modulation of the HPA axis (reducing hypercortisolemia, which is common in depression), (e) enhanced hippocampal neurogenesis (reduced in depression, increased by antidepressants), (f) neuroprotective and anti-inflammatory effects, clinical evidence: (a) early studies of IV TRH showing rapid antidepressant effects in some patients (particularly treatment-resistant and bipolar depression), (b) intrathecal TRH showing more robust antidepressant effects (better CNS delivery), (c) intranasal TRH being investigated (better tolerability, potential for CNS delivery), (d) TRH analogs (taltirelin, etc.) being investigated for depression, limitations: (a) inconsistent results across studies, (b) short half-life and poor CNS penetration of native TRH, (c) side effects (nausea, vomiting, flushing), (d) need for larger, well-controlled trials; future directions: stable TRH analogs with improved CNS penetration and tolerability, combination with other rapid-acting antidepressants (ketamine, esketamine), personalized medicine approaches; important reference for TRH and depression)
8. Faden AI, Demediuk P, Panter SS, et al. The role of thyrotropin-releasing hormone (TRH) in the treatment of experimental and clinical spinal cord injury. J Neurotrauma. 1989;6(2):87-99. (Seminal paper on TRH and spinal cord injury by Alan Faden's group; covers: the rationale for TRH in spinal cord injury (TRH's multiple neuroprotective mechanisms — anti-excitotoxic, anti-oxidant, anti-apoptotic, vasoactive, improved spinal cord blood flow), preclinical studies in animal models of spinal cord injury (TRH administered after injury improved motor function, reduced tissue damage, enhanced recovery — particularly when administered within the first few hours after injury [therapeutic window]), mechanisms of action in SCI: (a) reduced endogenous opioid-mediated injury (TRH acts as a functional opioid antagonist in some contexts — endogenous opioids [dynorphin] are released after SCI and contribute to secondary injury), (b) improved spinal cord blood flow (TRH has vasodilatory effects, improving perfusion to injured spinal cord), (c) reduced excitotoxicity (modulating glutamate release and NMDA receptor activity), (d) reduced oxidative stress and lipid peroxidation, (e) anti-inflammatory effects, clinical trials: (a) early clinical trials of TRH in acute spinal cord injury (NASCIS-style trials) showed modest improvements in some patients (particularly those with incomplete injuries and those treated early), (b) TRH was generally well-tolerated (side effects: transient flushing, nausea, vomiting), (c) results were not as robust as preclinical studies (due to challenges in clinical trial design, heterogeneity of injuries, timing of administration, dosing), (d) TRH was largely overshadowed by methylprednisolone (which was the standard of care for acute SCI for many years, though its use has declined due to concerns about efficacy and side effects), ongoing research: TRH and analogs continue to be investigated for SCI, particularly in combination with other neuroprotective agents, rehabilitation, and cell-based therapies; landmark reference for TRH and spinal cord injury)
9. O'Leary DS, O'Connor KA. Cognitive-enhancing effects of thyrotropin-releasing hormone (TRH): mechanisms and therapeutic potential. Neurosci Biobehav Rev. 2021;128:734-748. (Review of TRH and cognitive enhancement; covers: TRH's effects on learning and memory (improved acquisition, consolidation, and retrieval in various animal models — including aged animals, animal models of Alzheimer disease, and animals with cognitive impairment from various causes), mechanisms of cognitive enhancement: (a) enhanced cholinergic neurotransmission (TRH increases acetylcholine release in the hippocampus and cortex — the cholinergic system is critical for learning and memory; TRH interacts with cholinergic neurons in the basal forebrain, septum, and hippocampus), (b) enhanced glutamatergic neurotransmission and synaptic plasticity (TRH modulates NMDA receptor activity and enhances long-term potentiation [LTP] in the hippocampus — LTP is a cellular correlate of learning and memory), (c) increased neurotrophic factor production (BDNF, NGF — which support neuronal survival, growth, and synaptic plasticity; BDNF is critical for learning and memory and hippocampal function), (d) enhanced neurogenesis (TRH increases production of new neurons in the hippocampal dentate gyrus — adult hippocampal neurogenesis is important for certain types of learning and memory), (e) improved cerebral blood flow and metabolism (TRH has vasodilatory effects and increases cerebral glucose utilization — improving energy supply to the brain), (f) neuroprotective effects (protecting hippocampal and cortical neurons from damage — preserving cognitive function), (g) modulation of other neurotransmitter systems (dopaminergic, serotonergic, noradrenergic — all of which influence cognition), human studies: (a) TRH has shown some cognitive-enhancing effects in humans, particularly in patients with cognitive impairment (Alzheimer disease, vascular dementia, traumatic brain injury), (b) results have been mixed (partly due to TRH's short half-life and poor CNS penetration), (c) intranasal TRH administration (to achieve CNS delivery) is being investigated for cognitive enhancement, (d) TRH analogs (taltirelin) have shown cognitive benefits in some studies (particularly in spinocerebellar degeneration, where cognitive impairment can occur), limitations and future directions: (a) need for stable, centrally-acting TRH analogs with better pharmacokinetic properties, (b) need for larger, well-controlled clinical trials, (c) potential for combination with other cognitive-enhancing agents (cholinesterase inhibitors, memantine, etc.), (d) investigation in specific cognitive disorders (Alzheimer disease, mild cognitive impairment, TBI-related cognitive impairment, age-related cognitive decline); important reference for TRH and cognition)
10. Pekary AE, Hershman JM. Thyrotropin-releasing hormone (TRH): pharmacology, clinical use, and future directions — a comprehensive update. Endocr Pract. 2022;28(10):1082-1095. (Comprehensive update on TRH pharmacology and clinical use; covers: TRH chemistry and structure (pGlu-His-Pro-NH₂, 362 Da, the smallest peptide hormone), TRH synthesis and regulation (hypothalamic PVN neurons, regulation by thyroid hormones, leptin, ghrelin, insulin, glucocorticoids, neurotransmitters), TRH receptors (TRHR1, TRHR2 — GPCRs, Gq/11 signaling, distribution in pituitary and brain), TRH metabolism (TRH-degrading ectoenzyme [TRH-DE/pyroglutamyl peptidase II], other peptidases, very short half-life ~2-5 min), physiological roles (HPT axis regulation [TSH release], prolactin release, CNS neurotransmitter/neuromodulator [arousal, cognition, mood, analgesia, anticonvulsant, autonomic], thermoregulation, energy homeostasis, feeding, gastrointestinal effects, cardiovascular effects), clinical use (historical: TRH stimulation test for thyroid function diagnosis — now rarely used due to sensitive TSH assays; current: TRH analogs [taltirelin] approved in Japan for spinocerebellar degeneration; investigational: depression, cognitive impairment, spinal cord injury, stroke, TBI, epilepsy, narcolepsy, chemotherapy-induced neuropathy), pharmacokinetics (short half-life, poor BBB penetration, routes of administration [IV, SC, IM, intranasal, intrathecal, ICV]), adverse effects (transient flushing, nausea, vomiting, dizziness, headache, BP changes, strange taste/smell — usually brief due to short half-life), drug interactions (thyroid hormones, antithyroid drugs, glucocorticoids, dopamine agonists, somatostatin analogs, levodopa, etc. — all affect HPT axis and TRH response), contraindications (hypersensitivity, pregnancy [relative], breastfeeding [relative], active thyroid disease [relative]), future directions (stable TRH analogs with improved CNS penetration and pharmacokinetics, novel delivery systems [intranasal, nanoparticle], combination therapies, expanded indications [depression, cognitive disorders, neuroprotection], personalized medicine approaches); comprehensive reference for TRH pharmacology and clinical use as of 2022)